Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.


The aim of this study was to prepare ciprofloxacin HCl (CIP)-encapsulated poly(dl-lactide-co-glycolide) (PLGA) copolymer nanoparticles and its antibacterial potential was evaluated with pathogenic bacteria, Escherichia coli (E. coli), in vitro and in vivo. CIP-encapsulated nanoparticles of PLGA were prepared by multiple emulsion solvent evaporation method. PLGA nanoparticles showed spherical shapes with particle sizes around 100-300 nm. Loading efficiency was lower than 50% (w/w) because of water-solubility properties of CIP. At drug release study, CIP showed initial burst effect for 12 h and then continuously released for 2 weeks. At in vitro antibacterial activity test, CIP-encapsulated nanoparticles showed relatively lower antibacterial activity compared to free CIP due to the sustained release characteristics of nanoparticles. However, CIP-encapsulated PLGA nanoparticles (doses: 25 mg CIP/kg of mice) effectively inhibited the growth of bacteria due to the sustained release characteristics of nanoparticles, while free CIP was less effective on the inhibition of bacterial growth. These results indicated that CIP-encapsulated PLGA nanoparticles have superior effectiveness to inhibit the growth of bacteria in vivo.

Citations per Year

318 Citations

Semantic Scholar estimates that this publication has 318 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Jeong2008CiprofloxacinencapsulatedPN, title={Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.}, author={Young-Il Jeong and Hee-Sam Na and Dong-hyuk Seo and Dong-Gon Kim and Hyun-Chul Lee and Mi-Kyeong Jang and Sang-Kwon Na and Sung-Hee Roh and Sun-Il Kim and Jae Woon Nah}, journal={International journal of pharmaceutics}, year={2008}, volume={352 1-2}, pages={317-23} }